Patents by Inventor Andrew T. Watt

Andrew T. Watt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of src-c expression
    Publication number: 20040191904
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of src-c. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding src-c. Methods of using these compounds for modulation of src-c expression and for treatment of diseases associated with expression of src-c are provided.
    Type: Application
    Filed: November 5, 2003
    Publication date: September 30, 2004
    Inventors: C Frank Bennett, Andrew T Watt
  • Antisense modulation of tumor necrosis factor receptor 2 expression
    Publication number: 20040186069
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Tumor Necrosis Factor Receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Tumor Necrosis Factor Receptor 2. Methods of using these compounds for modulation of Tumor Necrosis Factor Receptor 2 expression and for treatment of diseases associated with expression of Tumor Necrosis Factor Receptor 2 are provided.
    Type: Application
    Filed: May 3, 2004
    Publication date: September 23, 2004
    Inventors: C. Frank Bennett, Andrew T. Watt
  • Antisense modulation of interferon gamma receptor 2 expression
    Publication number: 20040171575
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interferon gamma receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interferon gamma receptor 2. Methods of using these compounds for modulation of Interferon gamma receptor 2 expression and for treatment of diseases associated with expression of Interferon gamma receptor 2 are provided.
    Type: Application
    Filed: April 6, 2004
    Publication date: September 2, 2004
    Inventors: C. Frank Bennett, Andrew T. Watt
  • Modulation of CD24 expression
    Publication number: 20040097448
    Abstract: Compounds, compositions and methods are provided for modulating the expression of CD24. The compositions comprise oligonucleotides, targeted to nucleic acid encoding CD24. Methods of using these compounds for modulation of CD24 expression and for diagnosis and treatment of disease associated with expression of CD24 are provided.
    Type: Application
    Filed: November 19, 2002
    Publication date: May 20, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Andrew T. Watt
  • Modulation of TDP-1 expression
    Publication number: 20040097450
    Abstract: Compounds, compositions and methods are provided for modulating the expression of TDP-1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding TDP-1. Methods of using these compounds for modulation of TDP-1 expression and for diagnosis and treatment of disease associated with expression of TDP are provided.
    Type: Application
    Filed: November 19, 2002
    Publication date: May 20, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Andrew T. Watt
  • Modulation of checkpoint kinase 1 expression
    Publication number: 20040097446
    Abstract: Compounds, compositions and methods are provided for modulating the expression of checkpoint kinase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding checkpoint kinase 1. Methods of using these compounds for modulation of checkpoint kinase 1 expression and for diagnosis and treatment of disease associated with expression of checkpoint kinase 1 are provided.
    Type: Application
    Filed: November 16, 2002
    Publication date: May 20, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: William Gaarde, Susan M. Freier, Kenneth W. Dobie, Andrew T. Watt
  • Modulation of PIM-1 expression
    Publication number: 20040092463
    Abstract: Compounds, compositions and methods are provided for modulating the expression of PIM-1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding PIM-1. Methods of using these compounds for modulation of PIM-1 expression and for diagnosis and treatment of disease associated with expression of PIM-1 are provided.
    Type: Application
    Filed: November 11, 2002
    Publication date: May 13, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Andrew T. Watt
  • Antisense modulation of vascular endothelial growth factor receptor-2 expression
    Patent number: 6734017
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of vascular endothelial growth factor receptor-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding vascular endothelial growth factor receptor-2. Methods of using these compounds for modulation of vascular endothelial growth factor receptor-2 expression and for treatment of diseases associated with expression of vascular endothelial growth factor receptor-2 are provided.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: May 11, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Andrew T. Watt
  • Antisense modulation of histone deacetylase 4 expression
    Publication number: 20040077083
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Histone deacetylase 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Histone deacetylase 4. Methods of using these compounds for modulation of Histone deacetylase 4 expression and for treatment of diseases associated with expression of Histone deacetylase 4 are provided.
    Type: Application
    Filed: October 17, 2002
    Publication date: April 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Andrew T. Watt
  • Antisense modulation of BCL2-associated X protein expression
    Publication number: 20040077583
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of BCL2-associated X protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BCL2-associated X protein. Methods of using these compounds for modulation of BCL2-associated X protein expression and for treatment of diseases associated with expression of BCL2-associated X protein are provided.
    Type: Application
    Filed: December 5, 2003
    Publication date: April 22, 2004
    Inventors: Hong Zhang, Andrew T. Watt
  • Antisense modulation of CD36 expression
    Publication number: 20040076621
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD36. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD36. Methods of using these compounds for modulation of CD36 expression and for treatment of diseases associated with expression of CD36 are provided.
    Type: Application
    Filed: October 16, 2002
    Publication date: April 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Andrew T. Watt
  • Antisense modulation of Notch (Drosophila) homolog 4 expression
    Publication number: 20040077569
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Notch (Drosophila) homolog 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Notch (Drosophila) homolog 4. Methods of using these compounds for modulation of Notch (Drosophila) homolog 4 expression and for treatment of diseases associated with expression of Notch (Drosophila) homolog 4 are provided.
    Type: Application
    Filed: October 16, 2002
    Publication date: April 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventor: Andrew T. Watt
  • Antisense modulation of histone deacetylase 4 expression
    Publication number: 20040077084
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Histone deacetylase 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Histone deacetylase 4. Methods of using these compounds for modulation of Histone deacetylase 4 expression and for treatment of diseases associated with expression of Histone deacetylase 4 are provided.
    Type: Application
    Filed: October 17, 2002
    Publication date: April 22, 2004
    Applicants: Isis Pharmaceuticals Inc., Abbott Laboratories
    Inventors: Andrew T. Watt, Steven Davidsen, Junling Li, Keith Glaser
  • Antisense modulation of CD36 expression
    Publication number: 20040077567
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD36. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD36. Methods of using these compounds for modulation of CD36 expression and for treatment of diseases associated with expression of CD36 are provided.
    Type: Application
    Filed: October 16, 2002
    Publication date: April 22, 2004
    Applicants: Isis Pharmaceuticals Inc., Abbott Laboratories
    Inventors: Andrew T. Watt, Randy Lane Bell
  • Antisense modulation of Notch (Drosophila) homolog 4 expression
    Publication number: 20040077568
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Notch (Drosophila) homolog 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Notch (Drosophila) homolog 4. Methods of using these compounds for modulation of Notch (Drosophila) homolog 4 expression and for treatment of diseases associated with expression of Notch (Drosophila) homolog 4 are provided.
    Type: Application
    Filed: October 16, 2002
    Publication date: April 22, 2004
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Andrew T. Watt, Randy Lane Bell
  • Antisense modulation of PPAR-delta expression
    Publication number: 20040063129
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PPAR-delta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPAR-delta. Methods of using these compounds for modulation of PPAR-delta expression and for treatment of diseases associated with expression of PPAR-delta are provided.
    Type: Application
    Filed: September 5, 2003
    Publication date: April 1, 2004
    Inventors: William Gaarde, Susan M. Freier, Andrew T. Watt
  • Antisense inhibition of vascular endothelial growth factor receptor-1 expression
    Patent number: 6710174
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of vascular endothelial growth factor receptor-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding vascular endothelial growth factor receptor-1. Methods of using these compounds for modulation of vascular endothelial growth factor receptor-1 expression and for treatment of diseases associated with expression of vascular endothelial growth factor receptor-1 are provided.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: March 23, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Andrew T. Watt
  • Antisense modulation of urokinase plasminogen activator expression
    Publication number: 20040043957
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of urokinase plasminogen activator. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding urokinase plasminogen activator. Methods of using these compounds for modulation of urokinase plasminogen activator expression and for treatment of diseases associated with expression of urokinase plasminogen activator are provided.
    Type: Application
    Filed: September 19, 2003
    Publication date: March 4, 2004
    Inventors: Brenda F. Baker, Susan M. Freier, Andrew T. Watt
  • Antisense modulation of complement component C3 expression
    Publication number: 20040043956
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of complement component C3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding complement component C3. Methods of using these compounds for modulation of complement component C3 expression and for treatment of diseases associated with expression of complement component C3 are provided.
    Type: Application
    Filed: August 18, 2003
    Publication date: March 4, 2004
    Inventors: Mark J. Graham, Andrew T. Watt
  • Antisense modulation of apaf-1 expression
    Publication number: 20040023914
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Apaf-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targetd to nucleic acids encoding Apaf-1. Methods of using these compounds for modulation of Apaf-1 expression and for treatment of diseases associated with expression of Apaf-1 are provided.
    Type: Application
    Filed: August 25, 2003
    Publication date: February 5, 2004
    Inventors: Hong Zhang, Andrew T. Watt